JD Health stocks jumped more than 6% in Hong Kong. Its third-quarter operating profit increased over 1.25 times year-on-year, alongside establishing strategic collaborations with several renowned pharmaceutical companies.

On November 13, JD Health announced its third-quarter results for 2025. The group achieved revenue of RMB 17.12 billion, a year-on-year increase of 28.7%, and an operating profit of RMB 1.243 billion, up 125.3% compared to the previous year.

In the third quarter of 2025, JD Health signed strategic cooperation agreements with prominent pharmaceutical companies such as Lilly (LLY), Innovent Biologics (01801), Eisai China, and Bayer China. New drugs, including Eisai's original innovative medication, Dayvigo® (lemborexant tablets), Hengrui’s new dry eye drug Hengqin® (perfluorohexyloctane eye drops), and Bayer’s Daxalt® lactulose were launched on JD Health's platform, reinforcing JD Health's position as the leading station for exclusive new drug releases. Beyond pharmaceuticals, new health products such as Centrum Silver® unveiled by Haleon and the first domestic formula medical food for phenylketonuria, Special Love Benjia, launched by Sheng Tong Medical Nutrition were all available for launch on JD Health's comprehensive platform.

In September 2025, JD Health completed a collaboration agreement with Huazhong University of Science and Technology's Tongji Medical College Affiliated Union Hospital, aspiring to build a nationally leading smart outpatient patient service platform. The collaboration will advance the application of JD Zhuoyi AI products in hospital outpatient service scenarios, establishing a full-process AI-assisted system to offer patients a more convenient medical experience. They will also deepen cooperation in remote medical services, jointly exploring new models of "Internet + Medical Health" services.